Organ-specific therapy in critical illness: interfacing molecular mechanisms with physiological interventions.
Sepsis and SIRS is the outward manifestation of a generalized uncontrolled inflammatory response, which, if sustained, induces widespread endothelial damage and MODS. Immunomodulating therapies, at present, have proven ineffective in reducing morbidity and mortality, presumably because of the heterogeneous nature of sepsis and septic shock and the reciprocating and redundant nature of this inflammatory cascade. Organ-specific therapies can support life but impair both organ-specific function and remote organ function. Novel therapies aimed at minimizing further organ dysfunction may improve outcome in a cost-effective fashion by preventing both further primary organ dysfunction or remote organ dysfunction secondary to the subsequent activation of the inflammatory response.
Pinsky
M R
MR
Department of Anesthesiology and Critical Care Medicine, University of Pittsburgh Medical Center 15261, USA.
D000818:Animals; D001187:Artificial Organs; D003131:Combined Modality Therapy; D003422:Critical Care; D016638:Critical Illness / Q000628:therapy*; D016207:Cytokines / Q000502:physiology; D006801:Humans; D009102:Multiple Organ Failure / Q000503:physiopathology / Q000628:therapy; D009928:Organ Specificity; D012128:Respiratory Distress Syndrome / Q000503:physiopathology / Q000628:therapy; D018746:Systemic Inflammatory Response Syndrome / Q000503:physiopathology / Q000628:therapy*
D016207:Cytokines